Literature DB >> 27785703

The effect of S1P receptor signaling pathway on the survival and drug resistance in multiple myeloma cells.

Di Fu1, Yingchun Li1, Jia Li1, Xiaoyan Shi1, Ronghui Yang1, Yuan Zhong1, Huihan Wang1, Aijun Liao2.   

Abstract

Multiple myeloma (MM) remains incurable by conventional chemotherapy. Sphingosine-1-phosphate (S1P) receptor-mediated signaling has been recently demonstrated to have critical roles in cell survival and drug resistance in a number of hematological malignancies. To dissect the roles of S1P receptor pathway in MM, we systematically examined cell viability and protein expression associated with cell survival and drug resistance in MM cell lines upon treatment with either pathway activator (S1P) or inhibitor (FTY720). Our results reveal that FTY720 inhibits cell proliferation by downregulating expression of target genes, while S1P has an opposite effect. Knocking down of S1P receptor S1P5R results in a reduction of cell survival-related gene expression; however, it does not have impacts on expression of drug resistance genes. These results suggest that S1P signaling plays a role in cell proliferation and drug resistance in MM, and targeting this pathway will provide a new therapeutic direction for MM management.

Entities:  

Keywords:  Cell survival; Drug resistance; Multiple myeloma (MM); Sphingosine-1-phosphate (S1P); Sphingosine-1-phosphate receptors (S1PRs)

Mesh:

Substances:

Year:  2016        PMID: 27785703     DOI: 10.1007/s11010-016-2854-3

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  37 in total

1.  Transduction of intracellular calcium signals through G protein-mediated activation of phospholipase C by recombinant sphingosine 1-phosphate receptors.

Authors:  S An; T Bleu; Y Zheng
Journal:  Mol Pharmacol       Date:  1999-05       Impact factor: 4.436

2.  Sphingosine analog fingolimod (FTY720) increases radiation sensitivity of human breast cancer cells in vitro.

Authors:  Giulia Marvaso; Agnese Barone; Nicola Amodio; Lavinia Raimondi; Valter Agosti; Emanuela Altomare; Valerio Scotti; Angela Lombardi; Roberto Bianco; Cataldo Bianco; Michele Caraglia; Pierfrancesco Tassone; Pierosandro Tagliaferri
Journal:  Cancer Biol Ther       Date:  2014-03-21       Impact factor: 4.742

Review 3.  Emerging biology of sphingosine-1-phosphate: its role in pathogenesis and therapy.

Authors:  Richard L Proia; Timothy Hla
Journal:  J Clin Invest       Date:  2015-04-01       Impact factor: 14.808

4.  FTY720 enhances chemosensitivity of colon cancer cells to doxorubicin and etoposide via the modulation of P-glycoprotein and multidrug resistance protein 1.

Authors:  Ying Xing; Zhi Hong Wang; Dong Hong Ma; Ying Han
Journal:  J Dig Dis       Date:  2014-05       Impact factor: 2.325

5.  Sphingosine kinase 1 overexpression contributes to cetuximab resistance in human colorectal cancer models.

Authors:  Roberta Rosa; Roberta Marciano; Umberto Malapelle; Luigi Formisano; Lucia Nappi; Claudia D'Amato; Valentina D'Amato; Vincenzo Damiano; Gabriella Marfè; Silvana Del Vecchio; Antonella Zannetti; Adelaide Greco; Alfonso De Stefano; Chiara Carlomagno; Bianca Maria Veneziani; Giancarlo Troncone; Sabino De Placido; Roberto Bianco
Journal:  Clin Cancer Res       Date:  2012-11-19       Impact factor: 12.531

6.  Sphingosine-1-phosphate activates chemokine-promoted myeloma cell adhesion and migration involving α4β1 integrin function.

Authors:  David García-Bernal; Javier Redondo-Muñoz; Ana Dios-Esponera; Raphaël Chèvre; Elvira Bailón; Mercedes Garayoa; Nohemí Arellano-Sánchez; Norma C Gutierrez; Andrés Hidalgo; Angeles García-Pardo; Joaquin Teixidó
Journal:  J Pathol       Date:  2013-01       Impact factor: 7.996

7.  Thalidomide-induced antiangiogenic action is mediated by ceramide through depletion of VEGF receptors, and is antagonized by sphingosine-1-phosphate.

Authors:  Takeshi Yabu; Hidekazu Tomimoto; Yoshimitsu Taguchi; Shohei Yamaoka; Yasuyuki Igarashi; Toshiro Okazaki
Journal:  Blood       Date:  2005-03-01       Impact factor: 22.113

8.  FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.

Authors:  Paolo Neviani; Ramasamy Santhanam; Joshua J Oaks; Anna M Eiring; Mario Notari; Bradley W Blaser; Shujun Liu; Rossana Trotta; Natarajan Muthusamy; Carlo Gambacorti-Passerini; Brian J Druker; Jorge Cortes; Guido Marcucci; Ching-Shih Chen; Nicole M Verrills; Denis C Roy; Michael A Caligiuri; Clara D Bloomfield; John C Byrd; Danilo Perrotti
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

9.  S1P induced changes in epithelial ovarian cancer proteolysis, invasion, and attachment are mediated by Gi and Rac.

Authors:  Kathleen M Devine; Yoel Smicun; Joanie Mayer Hope; David A Fishman
Journal:  Gynecol Oncol       Date:  2008-05-29       Impact factor: 5.482

Review 10.  Sphingosine kinase 1 as an anticancer therapeutic target.

Authors:  Ying Gao; Fei Gao; Kan Chen; Mei-li Tian; Dong-li Zhao
Journal:  Drug Des Devel Ther       Date:  2015-06-23       Impact factor: 4.162

View more
  5 in total

Review 1.  Role of Sphingolipids in Multiple Myeloma Progression, Drug Resistance, and Their Potential as Therapeutic Targets.

Authors:  Daniela N Petrusca; Kelvin P Lee; Deborah L Galson
Journal:  Front Oncol       Date:  2022-06-08       Impact factor: 5.738

2.  Doxorubicin effect is enhanced by sphingosine-1-phosphate signaling antagonist in breast cancer.

Authors:  Eriko Katsuta; Li Yan; Masayuki Nagahashi; Ali Raza; Jamie L Sturgill; Debra E Lyon; Omar M Rashid; Nitai C Hait; Kazuaki Takabe
Journal:  J Surg Res       Date:  2017-06-29       Impact factor: 2.192

3.  PIWI-Interacting RNA-004800 Is Regulated by S1P Receptor Signaling Pathway to Keep Myeloma Cell Survival.

Authors:  Huanxin Ma; Huihan Wang; Fei Tian; Yuan Zhong; Zhuogang Liu; Aijun Liao
Journal:  Front Oncol       Date:  2020-04-15       Impact factor: 6.244

4.  Decreased Activity of Blood Acid Sphingomyelinase in the Course of Multiple Myeloma.

Authors:  Marzena Wątek; Ewelina Piktel; Joanna Barankiewicz; Ewa Sierlecka; Sylwia Kościołek-Zgódka; Anna Chabowska; Łukasz Suprewicz; Przemysław Wolak; Bonita Durnaś; Robert Bucki; Ewa Lech-Marańda
Journal:  Int J Mol Sci       Date:  2019-11-30       Impact factor: 5.923

Review 5.  Molecular Pharmacology and Novel Potential Therapeutic Applications of Fingolimod.

Authors:  Safura Pournajaf; Leila Dargahi; Mohammad Javan; Mohammad Hossein Pourgholami
Journal:  Front Pharmacol       Date:  2022-02-16       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.